December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

226.92 -4.95 (-2.13%)
Streaming Delayed Price Updated: 2:40 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 3 Next >
News headline image
WIN Advisors Cuts Its FTC Stake by $10.6 Million -- Here's What Investors Should Know ↗
This fund tracks a rules-based index targeting U.S. large-cap growth stocks, using a systematic approach to portfolio construction. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
The Smartest Vanguard ETF to Buy With $1,000 Right Now ↗
This ETF is built to outperform in down markets. 
Via The Motley Fool
Topics ETFs
News headline image
Palladyne AI CEO Touts Expanded Backlog, Deeper Defense Engagement After Q4 Beat Sends PDYN Stock Soaring ↗
Palladyne AI reported a loss of $0.04 per share, down from a loss of $1.75 per share during the same quarter a year ago, and better than Wall Street’s expectations of a loss of $0.14 per share. 
Via Stocktwits
Topics Artificial Intelligence Stocks
Lyft Draws Investor Attention After Wedbush Downgrades Stock Amid Autonomous Vehicle Risks ↗
Via Stocktwits
Toll Brothers Stock Slides After-Hours On Q4 Miss And Softer Delivery Forecast ↗
Via Stocktwits
American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act ↗
Via Stocktwits
Uber In Talks With Getir To Expand Delivery Services In Turkey: Report ↗
Via Stocktwits
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
The biotech company reported statistically significant Phase 3 data for QTORIN gel. 
Via Stocktwits
News headline image
Why Did PDYN Stock Pop Over 10% In Pre-Market Today? ↗
The company signed an agreement with a major U.S. defense prime contractor to supply a subsystem that supports missile propulsion. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious? ↗
The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. 
Via Stocktwits
News headline image
Why Is CorMedix Stock Rising Today? ↗
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study. 
Via Stocktwits
News headline image
Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit ↗
While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg. 
Via Stocktwits
BHVN Stock Tumbled A Whopping 44% Today – What Did The FDA Letter Say? ↗
Via Stocktwits
News headline image
JPMorgan Investment Banking Chief Plans Exit After 45 Years As Bank Ramps Up AI And Braces For $105B Costs: Report ↗
According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking. 
Via Stocktwits
Topics Artificial Intelligence Retirement
News headline image
Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business ↗
im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
ServiceNow Stock Is Down 5% Today — What’s Weighing On The Shares? ↗
KeyBank downgraded ServiceNow to ‘Underweight’ from ‘Sector Weight’ with a price target of $775. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook ↗
The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder ↗
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management. 
Via Stocktwits
News headline image
Micron To Stop Selling Crucial Consumer Products As It Heightens Focus On Larger Customers ↗
The company said that it will continue to ship Crucial products to consumers through the end of February 2026. 
Via Stocktwits
News headline image
Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum ↗
Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly. 
Via Stocktwits
News headline image
Why ANF Stock Is Soaring Before The Bell Today? ↗
Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise. 
Via Stocktwits
News headline image
Micron Stock Draws Investor Attention Following A Price Target Boost From UBS ↗
UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist. 
Via Stocktwits
News headline image
AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial ↗
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios... 
Via Stocktwits
News headline image
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer. 
Via Stocktwits
News headline image
Why Did Scholar Rock Soar 26% Today? ↗
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year. 
Via Stocktwits
Topics Earnings
News headline image
Uber COO Says Robotaxi Tech Is Largely Ready But Hardware Costs Are Still Too High ↗
Uber has partnerships in place with multiple robotaxi companies, including Pony AI, WeRide and Alphabet Inc’s Waymo. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance ↗
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million. 
Via Stocktwits
Topics Earnings
News headline image
2 Vanguard ETFs to Buy Hand Over Fist and 1 to Avoid ↗
Low-cost ETFs are excellent ways to build a diversified stock portfolio without incurring high fees. 
Via The Motley Fool
Topics ETFs
News headline image
Fiserv Shares Plunge 44% In Record One-Day Drop As Company Gets Wall Street Downgrades On Leadership Changes, Forecast Cuts ↗
Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns." 
Via Stocktwits
News headline image
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗
76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment. 
Via Stocktwits
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.